top of page

2021 Articles

Volume 3 Issue 1

Ayahuasca Tea in the United States: Why and how?

LJ Standish N.D., PhD; Juan Giménez Ph.D.; and Victoria G Hale, Ph.D.

Volume 3 Issue 1

Letter To The Editor

Scott Allen, M.D.; Rachel Allen, M.D.

Volume 3 Issue 1

Letter To The Editor

Megan Oxley, M.D.

Volume 3 Issue 1

Towards Consilience Between Research Paradigms and Spiritual Practice

Thomas D. Meacham, M.D.

Volume 3 Issue 2

Is Psychedelic Therapy Integrative Medicine?

Matthew Hicks, N.D., M.S.

Volume 3 Issue 2

Synthetic Cannabinoid-Induced Compulsive Sexual Behaviors: A Case Report

Amanda Klass, D.O.

Volume 3 Issue 2

A Comprehensive Review of Potential Uses of Ayahuasca in Psychiatry

Adam Bertroche, D.O.

Volume 3 Issue 2

Editorial Review: Trial of Psilocybin versus Escitalopram for Depression

Gershom Hernandez, M.D.

Volume 3 Issue 3

Newspaper Coverage of Psilocybin – Sentiment and Frequency (1989-2020)

Dax Oliver, M.A.

Volume 3 Issue 3

Practical and Ethical Considerations for Psychedelic Therapy and Integration Practices

Ismail Lourido Ali, J.D., Geoff Bathje, Ph.D., Roxanne R. Hallisey, B.S., Leslie Booher, J.D., M.B.A., Brooke Novick, L.M.F.T., Allison Feduccia, Ph.D.

Volume 3 Issue 3

Psychedelics and Response Duration

Gregory Jones, M.D.; Hunter Hinman M.D.; Elizabeth Mays M.D.; Daniel Liaou M.D.

Volume 3 Issue 4

Successful Self-Medication of a Major Depressive Episode with Repeated Administration of LSD: A Case Report

Jennifer Lyke, Ph.D. and Trey Brasher, B.S.

Volume 3 Issue 4

Psilocybin as an Abortive Treatment for Intractable Migraines: A Case Report

Alicia McCullough, M.D.

Volume 3 Issue 4

Internal Family Systems: A Therapeutic Model for Each Stage of the Psychedelic Experience

Nancy L. Morgan, Ph.D., Patrycja Radecka, Pg.Dip., and Coen de Koning, B.Sc.

bottom of page